Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 1.00 |
| ▸ | CPT2 | P23786 | 1/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111332 | 1.00 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL721435 | 1.00 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL17181773 | 1.00 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL17181757 | 1.00 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL2110910 | 1.00 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL27688847 | 1.00 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL108615 | 1.00 | ACLY (1.00) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL23068539 | 0.98 | ACLY (0.95) | ACLYCPT2HSPD1BLMHSPE1 | |
| Ammonia Solution, Strong SCHEMBL4780983 | 0.98 | ACLY (0.95) | ACLYCPT2HSPD1BLMHSPE1 | |
| SCHEMBL2821490 | 0.98 | ACLY (0.95) | ACLYCPT2HSPD1BLMHSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075731-A | Gambogic acid kidney delivery system based on beta-lactoglobulin reabsorption mediation and synthesis method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4157199-A1 | METHODS AND PHARMACEUTICAL PREPARATIONS FOR ELEVATING BLOOD HEMOGLOBIN AND OXYGEN SATURATION LEVELS WITH HYDROXYCITRIC ACID | Glykon Technologies Group, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| EP-4157254-A1 | METHODS AND PHARMACEUTICAL PREPARATIONS FOR ELEVATING KETONE UTILIZATION | Glykon Technologies Group, LLC. (US) | 2023-04-05 | — | — | EP | claimed |
| EP-4156970-A1 | REDUCING TRIGLYCERIDE LEVELS AND CORTISOL LEVELS WITH PHARMACEUTICAL PREPARATIONS | Glykon Technologies Group, LLC. (US) | 2023-04-05 | — | — | EP | claimed |
| CN-115006378-A | Medicine for preventing or treating metabolic diseases or metabolic dysfunction diseases | 西安莱格瑞生物科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| US-20190216756-A1 | ORGANIC ACIDS AS AGENTS TO DISSOLVE CALCIUM MINERALS IN PATHOLOGICAL CALCIFICATION AND USES THEREOF | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-07-18 | — | — | US | claimed |
| US-10285961-B2 | Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-14 | — | — | US | claimed |
| US-20150297545-A1 | ORGANIC ACIDS AS AGENTS TO DISSOLVE CALCIUM MINERALS IN PATHOLOGICAL CALCIFICATION AND USES THEREOF | UNIVERSITY OF HOUSTON SYSTEM (US) | 2015-10-22 | — | — | US | claimed |
| US-6706899-B2 | TETRAHYDRO-3-HYDROXY-5-OXO-2,3-FURANDICARBOXYLIC ACID (GARCINIA ACID) DERIVATIVES MADE BY REFLUXING GARCINIA ACID WITH ALCOHOLS USING AN ACID CATALYST; PHARMACEUTICAL APPLICATIONS | DEPARTMENT OF SCIENCE AND TECHNOLOGY, TECHNOLOGY BHAVAN (IN) | 2004-03-16 | — | — | US | claimed |
| US-20020042528-A1 | Novel acyclic chiral compound from garcinia acid and process for preparing the same | DEPARTMENT OF SCIENCE AND TECHNOLOGY, TECHNOLOGY BHAVAN (IN) | 2002-04-11 | — | — | US | claimed |
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | KOBAYASHI PHARMACEUTICAL CO LTD (JP) | 2026-05-07 | — | — | US | disclosed |
| CN-119816522-B | 5T4 antibody drug conjugate and application thereof | 上海美雅珂生物技术有限责任公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119894536-A | GPC3 antibody drug conjugate and application thereof | 乐普生物科技股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20220248744-A1 | NICOTINE MATERIALS, METHODS OF MAKING SAME, AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2022-08-11 | — | — | US | disclosed |
| CN-113952329-A | Application of gambogic acid in preparation of Src inhibitor and preparation of liver cancer treatment drug | 广州医科大学附属第二医院 | 2022-01-21 | — | — | CN | disclosed |
| US-6706899-B2 | TETRAHYDRO-3-HYDROXY-5-OXO-2,3-FURANDICARBOXYLIC ACID (GARCINIA ACID) DERIVATIVES MADE BY REFLUXING GARCINIA ACID WITH ALCOHOLS USING AN ACID CATALYST; PHARMACEUTICAL APPLICATIONS | DEPARTMENT OF SCIENCE AND TECHNOLOGY, TECHNOLOGY BHAVAN (IN) | 2004-03-16 | — | — | US | disclosed |
| US-20020042528-A1 | Novel acyclic chiral compound from garcinia acid and process for preparing the same | DEPARTMENT OF SCIENCE AND TECHNOLOGY, TECHNOLOGY BHAVAN (IN) | 2002-04-11 | — | — | US | disclosed |
| US-6147228-A | Convenient method for the large scale isolation of garcinia acid | DEPARTMENT OF SCIENCE AND TECHNOLOGY GOVERNMENT OF INDIA (IN) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042528-A1 | Novel acyclic chiral compound from garcinia acid and process for preparing the same | GK, ADH1A, CNR1 | ACLY 1190/4885CPT2 679/4885HSPD1 4574/4885 |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | CSGALNACT1, CD44, HCAR1 | ACLY 3090/4885CPT2 3121/4885HSPD1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.